We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Daniel Catenacci

Daniel Catenacci MD

Associate Professor of Medicine, The University of Chicago Medicine, Chicago, IL

Recent Contributions to PracticeUpdate:

  1. Updated Results From an Observational Study of Nivolumab for Advanced Gastric Cancer
  2. Trastuzumab Deruxtecan for Patients With HER2-Positive Advanced Gastric or GE Junction Adenocarcinoma
  3. Pembrolizumab vs Paclitaxel in Second-Line Treatment of Advanced Gastric Cancer
  4. Margetuximab Plus Checkpoint Inhibition for HER2+ Advanced GE Junction or Gastric Cancer
  5. Overcoming Heterogeneity to Develop Targeted Therapies for Gastroesophageal Cancer
  6. ASCO: Perioperative Targeting of HER2 for Gastroesophageal Cancer
  7. ASCO: Current Data and Outlook for Targeting HER2 in Gastrointestinal Cancer
  8. ASCO: Promising Results for Trastuzumab Deruxtecan for HER2+ Gastric Cancer
  9. ASCO: New Data and Implications for Immunotherapy in Gastric Cancer
  10. Nivolumab vs Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Most Read This Week

Recently Updated